Mylan sued by maker of anti-seizure drug

| Friday, July 26, 2013, 3:24 p.m.

Generic drugmaker Mylan Inc. was sued by the makers of Banzel after it was the first to ask the Food and Drug Administration to approve a generic version of the anti-seizure drug, the Cecil-based company said Friday.

Separately, Mylan said that it expects to begin selling a generic version of multiple sclerosis drug Copaxone next year after a federal appeals court reversed a lower court ruling that had gone against the company.

Last year, U.S. District Court for the Southern District of New York ruled that Mylan had infringed on a Copaxone patent held Teva Pharmaceuticals.

“We are very pleased with today's ruling. and we expect that it will allow Mylan to launch its generic version of Copaxone on May 25, 2014,” CEO Heather Bresch said.

In the lawsuit over Banzel, Mylan said Japanese drugmaker Eisai and Switzerland's Novartis Pharma AG filed a suit in federal court in Delaware this week alleging Mylan's copy of Banzel infringes on patents held by Eisai and Novartis.

Banzel had U.S. sales of $78.4 million in the 12 months ended March 31.

Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928 or anixon@tribweb.com.

Subscribe today! Click here for our subscription offers.

 

 
Show commenting policy
Trending